Vivaldi Capital Management LP Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Vivaldi Capital Management LP lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3,192.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,730 shares of the medical research company's stock after acquiring an additional 59,855 shares during the quarter. Amgen makes up 2.7% of Vivaldi Capital Management LP's portfolio, making the stock its 7th biggest position. Vivaldi Capital Management LP's holdings in Amgen were worth $17,453,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Waters Parkerson & CO. LLC raised its holdings in shares of Amgen by 17.3% during the fourth quarter. Waters Parkerson & CO. LLC now owns 4,581 shares of the medical research company's stock valued at $1,194,000 after acquiring an additional 677 shares in the last quarter. St. Clair Advisors LLC bought a new position in Amgen in the fourth quarter worth $730,000. Twinbeech Capital LP raised its holdings in Amgen by 178.4% in the fourth quarter. Twinbeech Capital LP now owns 5,204 shares of the medical research company's stock worth $1,356,000 after purchasing an additional 3,335 shares in the last quarter. Triglav Skladi D.O.O. bought a new position in Amgen in the fourth quarter worth $1,173,000. Finally, Two Sigma Advisers LP raised its holdings in Amgen by 96.9% in the fourth quarter. Two Sigma Advisers LP now owns 1,545,600 shares of the medical research company's stock worth $402,845,000 after purchasing an additional 760,700 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

AMGN stock traded down $0.24 during trading on Friday, reaching $271.66. The stock had a trading volume of 2,531,997 shares, compared to its average volume of 2,794,457. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock's 50 day moving average is $286.82 and its two-hundred day moving average is $286.72. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market cap of $146.07 billion, a PE ratio of 35.98, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter last year, the company earned $3.96 earnings per share. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is currently 86.86%.

Analyst Ratings Changes

AMGN has been the subject of a number of research reports. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Cantor Fitzgerald initiated coverage on Amgen in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price objective for the company. Piper Sandler decreased their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Finally, UBS Group reissued a "neutral" rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.